Amphastar Q4 Revenue Flat, EPS Miss Sends Shares Down 18.4%
AMPH is trading near its 52-week low of $16.645 (12% above the low).
Summary
Amphastar reported Q4 revenue of $171.2M, flat year-over-year, and an EPS miss that drove shares down about 18.4% to roughly $19.61. This follows a brutal Q1 where net income fell 75% and the company disclosed an FDA warning letter for manufacturing violations at its subsidiary. The board also added Anthony Pierce as an independent director effective July 9, expanding to 11 members — a governance move amid operational headwinds. The stock is now trading near $18.72, well below the post-earnings level, suggesting continued pressure. No forward guidance was provided, leaving the market to price in ongoing manufacturing and profitability risks.
At the time of this announcement, AMPH was trading at $18.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $825.4M. The 52-week trading range was $16.65 to $31.26. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.